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ABSTRACT
We examined a set of 805 cases that underwent DNA sequencing using the 
FoundationOne Heme (F1H) targeted sequencing panel and gene expression profiling. 
Known and likely variant calls from the mutational data were analyzed for significant 
associations with gene expression defined translocation cyclin D (TC) molecular 
subgroups. The spectrum of KRAS, NRAS, and BRAF codon mutations varied across 
subgroups with NRAS mutations at Q61 codon being common in hyperdiploid (HRD) and 
t(11;14) myeloma while being rare in MMSET and MAF. In addition, the presence of RAS-
RAF mutations was inversely associated with NFκB pathway activation in all subgroups 
excluding MAF. In the MMSET subgroup, cases with low FGFR3 expression frequently had 
RAS-RAF mutations. Conditional inference tree analysis determined that mutation and 
homozygous deletion of TP53, CDKN2C, and RB1 were key prognostic factors associated 
with adverse outcome in a non-relapse clinical setting. In conclusion, this study highlights 
the heterogeneity in the distribution and clinical outcomes of RAS codon and other 
mutations in multiple myeloma dependent upon primary molecular subgroup. 
INTRODUCTION
Analysis of myeloma plasma cells using 
cytogenetics and fluorescence in-situ hybridization (FISH) 
has formed the basis of genetic subgrouping in myeloma 
(MM) [1–3]. These investigations generated etiological 
groups based upon either the presence of a translocation 
into the immunoglobulin heavy chain (IGH) locus (40%) 
or hyperdiploidy (HRD). Further analysis identified the 
overexpression of a D-group cyclin as a key aberration 
that is uniformly dysregulated as part of a convergent 
evolutionary pathway integrating all of the genetic events 
leading to MM [4, 5]. In this respect, translocations 
into the 11q13 locus directly deregulate CCND1; 6p21 
CCND3; and 4p16 (MMSET), 16q23 (MAF), and 20q12 
(MAFB) indirectly deregulate CCND2. In contrast, the 
mechanistic basis for cyclin-D dysregulation in HRD 
myeloma is less clear [6].
Based on these genetic data, a MM classification 
incorporating the presence of translocations and D-group 
cyclin dysregulation, the Translocation Cyclin-D 
classification (TC) [5] was proposed which recognized 
eight molecular subgroups. Alternative classification 
models were also proposed with the most widely used 
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of these, the UAMS classification, recognizing seven 
molecular subgroups [7]. This classification framework 
was expanded upon by the HOVON group with additional 
subgroups defined by secondary features, e.g. NFκB 
activation and PRL3 expression [8]. 
Recently, next generation sequencing data has 
become available, which promises to further refine 
classification strategies. The spectrum of mutations in 
MM has been shown to be dominated by mutations in 
the RAS (43% of patients) and NFκB pathways (17%), 
and recurrent alterations in genes, including TP53, ATM, 
and ATR, and secondary translocations into MYC (8q24) 
that have strong associations with adverse risk [9]. It has 
also been shown that bi-allelic events in tumor suppressor 
genes, especially TP53, are associated with proliferation 
and high risk features which lead to progressive disease 
[10]. In this work, we investigate the associations between 
DNA mutation and GEP defined molecular subgroups 
of MM from a large data set with assessment by gene 
expression and targeted mutational panels (referred to 
as FoundationOne Heme, or F1H, below) with particular 
interest in RAS codon mutations.
RESULTS
Updated TC algorithm
We classify cases throughout according to an 
updated TC algorithm (TC-6) designed to accurately 
define molecular subgroups from gene expression data 
normalized by GCRMA. A detailed description of our 
methodology is found in the methods section below. 
This updated TC classification (TC-6) identifies six 
major subtypes (D1-HRD, D2, CCND1-11q13, CCND3-
6p21, MMSET, and MAF) and validated with ≥ 97.9% 
agreement across iFISH determined translocations on 
the MRC-IX data for each of t(4;14), t(11;14), and 
t(14;16) or t(14;20) (Supplementary Table 1). An ordered 
bar plot illustrates the distinct expression patterns 
of primary and secondary genes that discriminate 
subtypes (Supplementary Figure 1). Key copy number 
abnormalities and GEP70 high risk (HR) are differentially 
distributed across subgroups, e.g. 1q+, 13q-, and GEP70 
HR are enriched in MAF and MMSET subgroups (Table 1 
and Supplementary Figure 2A). 
Most frequently altered genes stratified by 
disease stage
Across our data set of cases with paired gene 
expression and FoundationOne mutational panels, we 
observed that NRAS, KRAS, and TP53 were the most 
commonly mutated genes. In total, 38.6% of all cases had 
a RAS-RAF mutation (KRAS alone 16.3%, NRAS alone 
18.3%, BRAF alone 3.0%, with co-occurrence in 1.1%) 
and 11.3% had a mutation or deletion in TP53 (Table 2). 
The rate of TP53 mutation in our data set is elevated when 
compared to prior studies [9] because of the heterogeneous 
disease stage, including non-baseline entries, of samples 
within our data set. Although heterogeneity in disease 
stage is a potential confounder of subsequent analyses 
(which we account for by verifying the significance of 
all main findings in multivariate analyses that include 
disease stage as a covariate), it also allows us to illustrate 
directly the association between specific gene alterations 
and progressive disease. For example, we found that in 
addition to TP53, CDKN2C and RB1 alterations were also 
significantly, or nearly significantly in the case of RB1, 
associated with progressive disease stage implicating 
these alterations as key markers of late stage disease 
(p-value < 0.001, 0.056 and 0.025 for TP53, RB1, and 
CDKN2C, respectively). We also observed that RAS-
RAF mutations, especially NRAS mutations of the Q61 
codon, were more common at or near relapse than at 
prior disease stages (20.6% of relapse cases have Q61 
NRAS mutation, 12.7% in prior disease stages: p-value 
= 0.005). None of the remaining key gene alterations 
were significantly associated with disease stage including 
mutations previously found to be associated with outcome, 
e.g. ATM/ATR [9].
Differential distribution of RAS codon and other 
mutations across TC subgroups
The distribution of RAS codon mutations is not 
uniform across TC subgroups. Most notably, NRAS 
mutations, especially at Q61, are common in HRD and 
t(11;14) MM yet rare in MAF and MMSET (18.5% of D1-
HRD (23.5%), D2 (12.3%), and CCND1-11q13 (20.9%) 
with Q61 NRAS vs 2.2% in MAF (2.1%) and MMSET 
(2.2%): p-value < 0.001; Table 3 and Figure 1). This 
differential pattern of Q61 NRAS mutations is independent 
of disease stage (subgroup-associated p-values remain 
highly significant in multivariate model including disease 
stage). The rarity of Q61 NRAS mutations in MMSET and 
MAF leads to a proportionally increased rate of KRAS and 
BRAF mutations in these subgroups (68% of MMSET 
and 80% of MAF cases with RAS-RAF mutations are 
KRAS or BRAF compared to 48% in D1-HRD, D2, and 
CCND1-11q13: p-value = 0.004). In addition, subgroups 
with elevated CCND2 expression (D2, MMSET, and 
MAF) have fewer RAS-RAF mutations overall compared 
to cases with elevated CCND1 expression (D1-HRD, 
CCND1-11q13) (30% of CCND2 high expressers with 
RAS-RAF mutation, 46% of CCND1 high: p-value 
< 0.001).
We also investigated whether specific RAS codon 
mutations were associated with expression of CD20 
(MS4A1) in t(11;14) myeloma as this is a common 
divisor of this subtype [11,12]. We found that across all 
t(11;14) cases, those with RAS-RAF mutations were to 
some extent less likely to overexpress CD20 (44.3% with 
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RAS-RAF mutations expressed CD20, 60.2% expressed 
without RAS-RAF mutation; p-value = 0.032). This 
negative association between RAS-RAF mutation and 
CD20 expression was found primarily in cases with 
Q61 NRAS mutations as only 33% (14/42) of such cases 
overexpressed CD20. When excluding these cases, we 
observed no significant difference in the rate of CD20 
overexpression among remaining cases (RAS-RAF 
mutated excluding Q61 NRAS vs non-RAS-RAF mutated 
cases: p-value = 0.708). Thus t(11;14) cases with RAS-
RAF mutations appear less likely to overexpress CD20, 
especially those with NRAS mutations at Q61. 
Table 1: Clinical and biological features of TC-6 subgroups
Count
Key Up-
Regulated 
Genes
Key Down-
Regulated 
Genes
Primary 
Translocation
UAMS 
Molecular 
Subgroups
1q+ 1p- 13q- 17p-
GEP70 
HR
Five-year 
OS
D1
HRD
299
(33.1)
ISL2
TNFSF10
SULF2
CCND2
S100A4
NES
None
HY (84.6)
PR (10.0)
29/193
(15.0)
39/193
(20.2)
37/137
(27.0)
11/145
(7.6)
28/299
(9.4)
74.9
D2 236
(26.2)
CCND2
PTP4A3
CCND1
DUSP6
None
LB (46.6)
PR (31.4)
73/148
(49.3)
27/148
(18.2)
52/101
(51.5)
7/105
(6.7)
30/236
(12.7)
72.9
CCND1
11q13
165
(18.3)
CCND1
SLC8A1
SULF2 t(11;14) CCND1
CD-2 (57.0)
CD-1 (35.2)
30/118
(25.4)
10/118
(8.5)
33/92
(35.9)
13/93
(14.0)
11/165
(6.7)
72.1
CCND3
6p21
17
(1.9)
CCND3
USP49
t(6;14) CCND3
CD-2 (52.9)
CD-1 (23.5)
2/9
(22.2)
0/9
(0.0)
3/5
(60.0)
0/7
(0.0)
1/17
(5.9)
82.4
MMSET 128
(14.2)
CCND2
WHSC1
FGFR3
t(4;14) MMSET
MS (94.5)
PR (5.5)
46/77
(59.7)
19/77
(24.7 )
40/56
(71.4)
5/55
(9.1)
33/128
(25.8)
60.2
MAF 57
(6.3)
CCND2
MAF or 
MAFB
NUAK1
NCAM1
t(14;16) MAF
t(14;20) MAFB
t(8:14) MAFA
MF (96.5)
28/37
(75.7)
7/37
(18.9)
20/31
(64.5)
5/33
(15.2)
26/57
(45.6)
52.6
Total 902
(100.0)
208/585
(35.6)
102/585
(17.4)
185/424
(43.6)
41/439
(9.3)
129 /902
(14.3)
70.5
Each TC-6 subgroup has a distinct biology that is reflected in varied distributions of copy number abnormalities (iFISH), 
GEP70 risk, and overall survival. 
Subgroups with over-expression of CCND2 (D2, MMSET, and MAF) had higher rates of 1q+ and 13q-. MAF and MMSET 
cases have the highest proportions of GEP70 HR and the poorest outcome. 
Figure 1: Distribution of RAS-RAF codon and other key alterations across TC-6 subgroups. NRAS mutations at Q61 are 
commonly seen in D1-HRD, D2, and CCND1-11q13 subgroups but rare among the MMSET and MAF subtypes. FGFR3 mutations are 
exclusive to the MMSET subtype and other genes are altered at a higher frequency in particular subgroups, e.g. MMSET cases are enriched 
for BIRC3 alterations and CCND2 expressing subgroups (D2, MMSET, and MAF) are enriched for TRAF3 alterations. Stacked bar plots 
represent frequencies of key alterations reported as percentages within each TC-6 subgroup. For the small number of cases (1.1%) with co-
occurrence of RAS-RAF mutations, only the mutation with highest variant allele frequency (VAF) was used. For the radial alteration plots, 
each individual slice corresponds to the mutational profile of one specific subject. 
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Overall, we observed an increased frequency in 
the rate of NRAS mutations, especially at Q61, when 
compared to other cancers. Our data set confirms prior 
work in MM that identified NRAS mutations as more 
common than KRAS and an increased frequency of NRAS 
mutations at Q61 [13]. An enrichment of mutations at Q61 
was not observed in cases with KRAS mutations (NRAS: 
83% Q61, 17% G12/G13 compared to KRAS: 51% Q61, 
49% G12/G13, p-value < 0.001; Table 2). While mutations 
at Q61 compose 60% of NRAS mutations in other cancers 
[14], we find this rate to be over 80% in MM likely due 
to the increased rate of NRAS mutations at Q61 observed 
in HRD and t(11;14) myeloma—subgroups that comprise 
the majority of MM. 
Other key mutations were enriched in specific 
subgroups. For example, BIRC3 was frequently altered in 
MMSET but rarely in other subgroups (14.6% of MMSET 
with alteration, 1.4% of others: p-value < 0.001; Table 3). 
In addition, CDKN2C and RB1 were more frequently 
altered in the D2 and MMSET subgroups (p-values 0.019 
and < 0.001, respectively). Mutations and deletions of 
TRAF3, a gene in the alternative NFκB pathway [15,16], 
were enriched in high expressers of CCND2 (9.2% of 
D2, MMSET, and MAF, 1.4% of D1-HRD and CCND1-
11q13: p-value < 0.001). A full compendium of gene 
mutation and deletion counts both overall and split across 
TC-6 and UAMS molecular subgroups is available in 
Supplementary Table 2.
Table 2: RAS-RAF codon and other key alterations by disease stage
Gene Total Mutations
Total 
Deletions
Untreated    
(n = 182)
In 
Treatment 
(n = 329)
At or Near 
Relapse  
(n = 294)
Cochran-
Armitage 
Trend Test 
p-value
Relapse vs 
Prior Stage 
p-value
RAS-RAF 311 
(38.6%)
57 (31.3%) 117 (35.6%) 137 (46.6%) < 0.001 0.001
KRAS 134 
(16.6%)
25 (13.7%) 55 (16.7%) 54 (18.4%) 0.195 0.370
G12/13 66 (8.2%) 15 (8.2%) 28 (8.5%) 23 (7.8%) 0.841 0.872
Q61 68 (8.4%) 10 (5.5%) 27 (8.2%) 31 (10.5%) 0.053 0.136
NRAS 151 
(18.8%)
26 (14.3%) 53 (16.1%) 72 (24.5%) 0.003 0.002
G12/13 26 (3.2%) 3 (1.6%) 11 (3.3%) 12 (4.1%) 0.156 0.407
Q61 125 
(15.5%)
23 (12.6%) 42 (12.8%) 60 (20.4%) 0.012 0.005
BRAF V600E 26 (3.2%) 6 (3.3%) 9 (2.7%) 11 (3.7%) 0.716 0.678
TP53 91 (11.3%) 3 (0.4%) 12 (6.6%) 32 (9.7%) 50 (17.0%) < 0.001 0.001
TRAF3 27 (3.4%) 14 (1.7%) 6 (3.3%) 19 (5.8%) 16 (5.4%) 0.363 0.861
FGFR3 25 (3.1%) 3 (1.6%) 11 (3.3%) 11 (3.7%) 0.225 0.563
RB1 23 (2.9%) 15 (1.9%) 5 (2.7%) 14 (4.3%) 19 (6.5%) 0.056 0.111
CDKN2C 6 (0.7%) 23 (2.9%) 3 (1.6%) 10 (3.0%) 16 (5.4%) 0.025 0.054
DNMT3A 26 (3.2%) 3 (1.6%) 13 (4.0%) 10 (3.4%) 0.373 0.999
ATM/ATR 32 (4.0%) 2 (1.1%) 20 (6.1%) 10 (3.4%) 0.398 0.657
TET2 23 (2.9%) 1 (0.1%) 4 (2.2%) 12 (3.6%) 8 (2.7%) 0.856 0.909
BIRC3 2 (0.2%) 21 (2.6%) 6 (3.3%) 8 (2.4%) 9 (3.1%) 0.955 0.965
Across the heterogeneous disease stages present in our data set, we observed that RAS-RAF mutations were more common at 
relapse than at prior disease stage, primarily due to increase of NRAS mutations of Q61 at relapse. In addition, alterations of 
TP53 are more common at relapse than prior disease stages, and mutation and deletion of RB1 and CDKN2C are significantly 
or near significantly associated with progressive disease stage.
All rows with either p-value < 0.01 are bolded. Two p-values are reported: a Cochran-Armitage trend test that examines 
progressive change in distribution across three disease stages and relapse vs prior disease stage Fisher exact test. Mutations 
and deletions are reported in first two columns, and their combined sum (alterations) is divided across disease stages. For cases 
with co-occurrence of RAS-RAF mutations, the mutation with highest variant allele frequency is reported here. 
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Table 3: RAS-RAF codon and other key alterations by TC-6 subgroup
Gene Total Mutations
Total 
Deletions
Most 
Common 
Subgroups
Count 
(Percentage)
Least 
Common 
Subgroups
Count 
(Percentage)
Fisher Exact 
Test 
p-value
RAS-RAF 311 (38.6%) D1-HRD, 
CCND1
192/414 
(46.4%)
D2, MMSET, 
MAF
115/381 
(30.2%)
< 0.001
KRAS 134 (16.6%) D1-HRD, 
MAF
55/261 
(21.1%)
D2, MMSET, 
CCND1
77/534 
(14.4%)
0.020
G12/13 66 (8.2%) MAF 7/48 
(14.6%)
D1-HRD, 
D2, CCND1, 
MMSET
58/747 
(7.8%)
0.162
Q61 68 (8.4%) D1-HRD, 
D2, CCND1
59/658 
(9.0%)
MMSET, 
MAF
8/137 
(5.8%)
0.309
NRAS 151 (18.8%) D1-HRD, 
D2, CCND1
140/658 
(21.3%)
MMSET, 
MAF
11/137 
(8.0%)
< 0.001
G12/13 26 (3.2%) MMSET, 
MAF
8/137 
(5.8%)
D1-HRD, D2, 
CCND1
18/658 
(2.7%)
0.107
Q61 125 (15.5%) D1-HRD, 
D2, CCND1
122/658 
(18.5%)
MMSET, 
MAF
3/137 
(2.2%)
< 0.001
BRAF 
V600E 26 (3.2%)
MMSET, 
MAF
7/137 
(5.1%)
D1-HRD, D2, 
CCND1
17/658 
(2.6%)
0.163
TP53 91 (11.3%) 3 (0.4%)
D1-HRD, 
CCND1, 
MAF
62/462 
(13.4%)
D2, MMSET
31/333 
(9.3%)
0.093
TRAF3 27 (3.4%) 14 (1.7%)
D2, 
MMSET, 
MAF
35/381 
(9.2%)
D1-HRD, 
CCND1
6/414 
(1.4%)
< 0.001
FGFR3 25 (3.1%) MMSET 25/89 
(28.1%)
D1-HRD, 
D2, CCND1, 
MAF
0/706 
(0.0%)
< 0.001
RB1 23 (2.9%) 15 (1.9%) D2, MMSET 23/333 
(6.9%)
D1-HRD, 
CCND1, MAF
15/462 
(3.2%)
0.019
CDKN2C 6 (0.7%) 23 (2.9%) D2, MMSET 22/333 
(6.6%)
D1-HRD, 
CCND1, 
MAF
7/462 
(1.5%)
< 0.001
DNMT3A 26 (3.2%) D2, CCND1, 
MMSET
21/534 
(3.9%)
D1, MAF
3/261 
(1.1%)
0.044
ATM/ATR 32 (4.0%) MMSET, MAF
12/137 
(8.8%)
D1-HRD, D2, 
CCND1
20/658 
(3.0%)
0.006
TET2 23 (2.9%) 1 (0.1%) D2, MAF 12/292 
(4.1%)
D1-HRD, 
CCND1, 
MMSET
11/503 
(2.2%)
0.129
BIRC3 2 (0.2%) 21 (2.6%) MMSET 13/89 
(14.6%)
D1-HRD, 
D2, CCND1, 
MAF
10/706 
(1.4%)
< 0.001
RAS-RAF and other key alterations are not distributed evenly across TC-6 subgroups. We have reported the most significant 
difference in distribution for each specific gene. A full breakdown of mutation and deletion by subgroup can be found in 
Supplementary Table 2. 
All rows with p-values < 0.01 are bolded. Mutations and deletions are reported in first two columns, and their combined sum 
(alterations) is divided across the TC-6 subgroups. CCND3-6p21 subgroup is not included in this subgroup analysis due to sample size 
restraints. For cases with co-occurrence of RAS-RAF mutations, the mutation with highest variant allele frequency is reported here.
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Patterns of differential expression associated 
with RAS-RAF mutations
Differential expression analysis revealed many 
genes to have patterns of expression highly associated 
with the presence of RAS-RAF and FGFR3 mutations. 
Probes for DUSP6, DKK1, SPRED2, COBLL1, and ETV5 
were the most significantly associated with presence 
of RAS-RAF or FGFR3 mutations across all cases 
(Supplementary Table 3 and Figure 2A–2E). Additional 
analyses revealed that for specific subgroups, certain 
genes were highly associated with the presence of RAS-
RAF mutations. For example, sprouty-related protein gene 
SPRED2, established as a negative regulator of MAPK/
ERK signaling [17,18], was positively associated with 
the presence of RAS-RAF mutations, especially in the 
CCND1-11q13 subgroup. This differential expression 
pattern of SPRED2 in CCND1-11q13 cases provides 
a nearly dichotomous split of RAS-RAF mutations at a 
certain threshold of SPRED2 expression, i.e. 81.4% of 
cases with SPRED2 expression above and 8.7% of cases 
with SPRED2 expression below had RAS-RAF mutations 
(79/97 cases with SPRED2 expression above 4.65 versus 
9/104 below; p-value < 0.001; Figure 2C). In addition, 
the expression of the oncogene RRAS2 has a dichotomous 
distribution across D1-HRD cases, i.e. differential clusters 
of low and high expressers, where high expression was 
negatively associated with presence of RAS-RAF 
mutations (17% of high RRAS2 expressers with RAS-
RAF mutations, 64% in low expressers; p-value < 0.001; 
Figure 2F). We note that these patterns of gene expression 
associated with RAS-RAF mutations are capable of further 
subtyping molecular subgroups of myeloma, especially in 
the D1-HRD, D2, and CCND1-11q13 subgroups where 
significant gene expression patterns were observed 
(Supplementary Figure 3).
We noted that two key genes observed to be 
significantly differentially expressed according to presence 
of RAS-RAF mutations were included in previous studies 
that defined the molecular subgroups of MM. Most 
notably, DUSP6, a negative regulator of MAPK/ERK 
signaling [19], is one of the top under-expressed genes 
in the LB (low bone) subgroup of the UAMS molecular 
subgroups and also under-expressed in the PRL3 subgroup 
of the HOVON model. We observed DUSP6 expression 
to be positively associated with the presence of RAS-
RAF mutation, thus these prior models of MM subtyping 
unknowingly identified cohorts that were negatively 
enriched for the presence of RAS-RAF mutations. We 
validated this by classifying our F1H cohort according to 
UAMS molecular subgroups and observed LB cases to 
have the lowest rate of RAS-RAF mutation (17.3%), while 
CD-1 (40.6%), HY (48.1%), and PR (43.8%) subgroups 
had significantly higher rates (LB RAS-RAF mutation 
rate vs other molecular subtypes: p-value = 0.001). 
In addition, the expression of DKK1, a known Wnt-
signaling antagonist [20], was previously described as 
up-regulated in HY and down-regulated in MF subgroups 
in the UAMS molecular subgroups. We observed similar 
patterns of expression in D1-HRD and MAF subgroups, 
and its positive association with the presence of RAS-RAF 
mutations (Figure 2B). Overall, due to the abundance of 
RAS-RAF mutations and distinct associated patterns of 
gene expression, gene-expression based subtyping in 
MM is likely to incorporate these clear transcriptional 
relationships either knowingly or unknowingly. 
NFκB signaling inversely associated with RAS-
RAF mutations
NFκB signaling, according to the 11-gene NFκB 
signature [21], varied across the TC subgroups with 
significantly elevated levels in the MAF subgroup 
(p-values < 0.001 in TT and F1H; 0.17 in MRC-IX; 
Supplementary Figure 2B). Furthermore, NFκB signaling 
was negatively associated with presence of RAS-RAF and 
FGFR3 mutations across all subgroups except for MAF 
(p-value < 0.001 for D1-HRD, D2, CCND1-11q13, and 
MMSET subgroups combined; p-value = 0.843 in MAF; 
Figure 3A). 
Unique mutational features of MMSET myeloma
MMSET cases are unique as they can overexpress 
and have activating mutations in FGFR3. Overall, 25 
MMSET cases had FGFR3 mutations (28.1%), 25 had a 
RAS-RAF mutation (28.1%), and 39 had neither (43.8%); 
co-occurrence of FGFR3 and RAS-RAF mutations was 
not observed (Figure 1), consistent with both RAS-RAF 
and FGFR3 mutations activating similar pathways and, 
therefore, being functionally redundant. The FGFR3 locus 
is lost in 26% of MMSET cases [22], and consistent with 
this, we see lower expression of FGFR3 in 20% (18 of 
89) of MMSET cases in the F1H dataset. Over half of 
these cases (56%) had a RAS-RAF mutation, while only 
21% of cases with high FGFR3 expression had RAS-RAF 
mutations, indicating that FGFR3 expression is more 
likely to be lost in the presence of a RAS-RAF mutation 
(p-value = 0.007; Figure 3B). In addition, both FGFR3 
and RAS-RAF mutated cases had lower NFκB signaling 
than those without either mutation (Figure 3A).
Outcome of RAS-RAF codon mutations across 
subgroups
Despite a relatively short follow-up and 
heterogeneity in disease stage across our data set, 
we observed highly significant patterns in outcome 
associated with specific RAS-RAF codon mutations. 
Among subgroups with significant enrichment of Q61 
NRAS mutations, we observed Q61 NRAS mutations to 
be associated with a favorable outcome in the t(11;14) 
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subgroup, and a less favorable outcome in the D1-HRD 
and D2 subgroups (p-value = 0.001, independent of 
disease stage; Supplementary Figure 4). 
For the MMSET subgroup, cases with RAS-RAF 
mutations had an inferior outcome compared to cases with 
FGFR3 mutations or those without RAS-RAF mutations 
(p-value = 0.004, independent of disease stage). In 
addition, only 1/25 cases (4%) with an FGFR3 mutation 
also had a CDKN2C or RB1 alteration, while 28% of 
cases with RAS-RAF mutations had one or more of these 
alterations (p-value = 0.049). This is in keeping with 
alterations in CDKN2C and RB1 being indicators of late 
stage disease [23,24], thus the absence of these alterations 
in FGFR3 mutated cases suggests FGFR3 mutations as 
early events and RAS-RAF mutations as markers of late 
stage disease in t(4;14) MM.
Figure 2: Differential gene expression patterns associated with presence of RAS-RAF mutations across TC-6 
subgroups. The gene expression levels of DUSP6, DKK1, SPRED2, ETV5, and COBLL1 were highly associated with the presence of 
RAS-RAF or FGFR3 mutations across all cases (A–E). COBLL1 expression is negatively associated with presence of RAS-RAF mutation 
while remaining genes are positively associated. The RAS viral oncogene, RRAS2, has a dichotomous expression pattern in the D1-HRD 
subgroup where high expressers of RRAS2 have few RAS-RAF mutations (F). Density curves are colored according to localized rate of 
RAS-RAF/FGFR3 mutation and represent probability distributions for mutated and non-mutated cases, separated by dividing horizontal 
lines. Vertical red lines indicate optimal thresholds of significance according to Fisher exact tests, limited to interior 60% of percentiles, 
where only highly significant p-values were reported (< 0.005). CCND3-6p21 subgroup not included due to sample size restraints (n =10). 
Gene expression represents log2 of GCRMA normalized data using the following probe or average of probes: DUSP6 – 208891_at, 
208892_s_at, 208893_s_at; DKK1 – 204602_at; SPRED2 – 212458_at; ETV5 – 203349_s_at; COBLL1 – 203641_s_at, 203642_s_at; and 
RRAS2 – 212589_at, 212590_at.
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Alterations of TP53, CDKN2C, and RB1 
associated with adverse outcome
A conditional inference tree analysis of all possible 
DNA variants against OS showed that alterations in TP53, 
CDKN2C, and RB1 were significant prognostic factors 
across the F1H data set when excluding cases at or near 
relapse (Figure 4A). The subset of 66 non-relapse cases 
(12.9% of all non-relapse cases) with one or more of these 
adverse alterations had an extremely poor prognosis with 
an 18-month OS rate of 34.1%—statistically similar to 
the rate observed in GEP70 HR cases (p-value = 0.157; 
Figure 4B-4C). The combination of GEP70 risk and 
presence of adverse DNA alterations stratified all non-
relapse cases into three arms with distinct clinical course: 
32 cases (GEP70 HR and any adverse alteration) with 
an extremely poor outcome (17.3% OS at 18-months), 
81 cases (GEP70 HR or any adverse alteration) with an 
intermediate outcome (60.3% OS rate at 18-months), and 
398 cases (no adverse alterations and GEP70 LR) with 
a standard outcome (86.5% OS at 18-months) (p-value 
< 0.001; Figure 4D). Overall, this subset of alterations 
(TP53, CDKN2C, and RB1) is significantly associated 
with progressive disease stage where 25.9% of cases at or 
near relapse had one or more of these alterations compared 
to 12.9% in prior disease stages (p-value < 0.001, Table 2).
In order to define a mechanistic basis for HR, we 
examined patterns of gene expression associated with these 
adverse alterations. We observed strong associations between 
CDKN2C deletions and low expression of FAF1, and that 
high expression of CDKN2C was associated with alterations 
of RB1. We also found cases exhibiting these expression 
patterns across two NDMM data sets, and observed 
significant associations with proliferation and outcome for 
cases exhibiting either expression pattern. Cases with either 
a low FAF1 expression signature (associated with CDKN2C 
deletion) or high CDKN2C expression signature (associated 
with RB1 alteration) had an 18-month OS rate of 26.9% 
compared to 73.5% in cases without either signature (p-value 
< 0.001; Figure 5Aii). In addition, cases with either adverse 
expression signature had elevated proliferation indexes, 
according to the 50-gene proliferation signature [25] (p-value 
< 0.001; Figure 5Aiii). These patterns of gene expression, 
outcome, and proliferation were validated in both the TT and 
MRC-IX datasets of NDMM cases (Figure 5B–5C).
We note that within the F1H data set, CDKN2C 
alterations (29 cases) and RB1 alterations (38 cases) 
did not co-occur in any single case. This observation, 
along with the disparate patterns of gene expression, is 
consistent with alterations in CDKN2C and RB1 offering 
mutually exclusive paths to elevated proliferation and 
high-risk behavior. 
DISCUSSION
We show for the first time a clear difference in 
mutational spectrum across the molecular subgroups of 
MM defined by an updated TC algorithm. Specifically, we 
Figure 3: NFκB signature across TC-6 subgroups and FGFR3 expression in MMSET subgroup. The 11-gene NFκB 
signature is significantly associated with presence of RAS-RAF or FGFR3 mutations in all TC-6 subgroups excluding MAF where cases 
without RAS-RAF mutations have higher levels of NFκB activation (A). When examining interaction of FGFR3 expression and RAS-RAF 
mutation in MMSET, we observed that 56% (10/18) cases with low FGFR3 expression have RAS-RAF mutations compared to 21% of 
remaining cases (15/71) (B).
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show that NRAS mutations at Q61 are common in HRD 
and t(11;14) myeloma but rare in MMSET and MAF. 
This heterogeneity in RAS codon mutations parallels the 
diversity in primary translocation and cyclin D initiating 
events in myeloma. These primary events yield diverse 
genetic backgrounds that likely influence the rate, type, 
and impact of the acquisition of secondary mutations and 
deletions. Overall, this analysis aims to describe the unique 
distribution and clinical impact of key mutations across 
the molecular subtypes of myeloma while highlighting the 
importance of defining RAS mutations at the codon level. 
Both primary TC event and RAS-RAF mutation 
have distinct resultant patterns in gene expression. We 
used the gene expression patterns associated with cyclin 
D and translocation events to generate an updated model 
that defines all cases according to six primary TC events. 
This model is unique from prior TC models in that it uses 
additional secondary genes, e.g. SLC8A1 up-regulation 
in t(11;14) or DSG2 up-regulation in t(4;14) myeloma, 
incorporated into a support vector machine (SVM) 
classification model to determine optimal subgroups in a 
simultaneous rather than dichotomous step-wise fashion. 
This model is distinct from the molecular subtyping 
models because it groups cytogenetically similar cases 
together rather than allowing secondary events to 
determine subgroup, e.g. cases with t(4;14) and t(11;14) 
may classify as PR (proliferative) in UAMS molecular 
subgroups. We also observed strong patterns of gene 
expression associated with the presence of RAS-RAF 
mutations. Most notably, DKK1, DUSP6, and SPRED2 
Figure 4: Alterations of TP53, CDKN2C, and RB1 showed significant association with overall survival in non-relapse 
clinical setting. Conditional inference tree analysis of all possible DNA alterations against outcome revealed that alterations in TP53, 
CDKN2C, and RB1 were significantly associated with an adverse outcome for all cases with disease stages prior to relapse (A). The 
subset of cases with one or more of these adverse alterations had an 18-month OS rate that was statistically similar to that of GEP70 HR 
cases (B, C). Combining GEP70 risk and the presence of adverse alterations identified three cohorts with distinct clinical course: poor, 
intermediate, and standard outcomes (D, E). 
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were positively associated with the presence of RAS-RAF 
mutations. This pattern was strongest in subgroups with 
higher rates of NRAS mutations at Q61, i.e. D1-HRD, 
D2, and CCND1-11q13. We suspect that the increased 
expression of MAPK/ERK antagonists (DUSP6 and 
SPRED2) associated with Q61 NRAS mutations is a 
result of a regulating transcriptional response attempting 
to counteract activating RAS mutations, i.e. a repeating 
negative feedback mechanism. 
We show that all non-MAF cases lacking a RAS-
RAF or FGFR3 mutation have increased NFκB signaling. 
This reciprocal relationship between NFκB signaling 
and activating RAS-RAF mutations is consistent with 
a functional similarity of signaling via these pathways 
Figure 5: CDKN2C and RB1 alterations elicit distinct patterns of gene expression that have significant impact on 
proliferation and clinical outcome in newly diagnosed MM. Differential expression analysis revealed highly significant patterns 
of expression associated with alteration in CDKN2C and RB1. Namely that cases with deletion of CDKN2C have lower expression of FAF1 
and that cases with alterations of RB1 have higher expression of CDKN2C (Ai). Cases with either of these distinct expression patterns had 
inferior outcomes (Aii) and higher 50-gene proliferation scores (Aiii). Identical patterns of inferior outcome and elevated proliferation 
were observed in both the Total Therapy and MRC-IX data sets of NDMM (B, C). In total, alterations in CDKN2C and RB1 offer mutually 
exclusive paths that culminate in similar high-risk behavior.
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and, therefore, functional redundancy. We propose, 
based on this observation, that MM is characterized 
by growth signaling delivered primarily via MAPK or 
NFκB pathways in a mutually exclusive fashion. The 
MAF subgroup is unique in this respect as all cases 
have elevated NFκB signaling irrespective of their RAS 
mutational status, likely indicative of their unique genetic 
background [26].
DNA alterations of TP53, CDKN2C, and RB1 
were identified as key markers of progressive disease 
and associated with adverse outcome in a non-relapse 
MM setting. We also presented the unique interaction 
between deletion of CDKN2C and alteration of RB1 where 
both were mutually exclusive with distinct downstream 
signals in gene expression, yet each impart similar 
paths to elevated proliferation and adverse outcome. As 
both CDKN2C and RB1 interact with G1/S cell cycle 
checkpoint through CDK4/6 [27–29], they are potentially 
targetable through CDK4/6 inhibition [30], for which it has 
been shown in other cancers that co-deletion of CDKN2C 
and CDKN2A with functional presence of RB1 increases 
sensitivity in cell lines [31]. A better understanding of the 
interaction of these two key prognostic markers in MM 
could open new possibilities for targeted therapy. Overall, 
this work aims to serve as a fundamental step in the 
transition from panel-based DNA assessment and GEP-
based expression analysis to RNA-Seq and whole genome 
assessments that fully examine the complete mutational 
landscape of MM. 
MATERIALS AND METHODS
A set of 805 UAMS GEP samples underwent 
targeted sequencing using the FoundationOne Heme (F1H) 
mutational assay (Foundation Medicine, Cambridge, MA) 
annotated for known and likely mutations and deletions 
with variant allele frequencies at or above five percent. 
Additionally, KRAS, NRAS, and BRAF mutations were 
limited to missense mutations annotated for known 
activating mutations: codons G12, G13, and Q61 for K 
and N RAS and V600E for BRAF. Additional mutations 
in non RAS-RAF genes included all varieties of short 
variants: frameshift, missense, nonsense, etc. This series 
has a median follow-up of 13.5 months with samples 
collected at various disease stages including 23% prior to 
treatment, 41% in treatment, and 36% at or near relapse 
(within 90 days +/– of progression event). This data set 
was analyzed for associations in mutation and deletion 
associated with TC subgroups.
An additional data set of 902 UAMS Myeloma 
Institute gene expression profiling (GEP) samples from 
newly diagnosed (NDMM) patients accrued to Total 
Therapy (TT) trials between 2000 and 2010 had a median 
follow-up of over 10 years and was used to develop an 
updated TC classification model. iFISH data for 1q+, 1p–, 
13q–, and 17p– gathered at baseline were available but not 
in full. Patients gave written informed consent for bone 
marrow sampling and the research was approved by the 
institutional review board of UAMS. This data set of 902 
NDMM cases was used to train the updated TC algorithm. 
For all GEP data, plasma cells were CD138-purified 
from bone marrow aspirates and processed on U133 Plus 
2.0 microarrays (Affymetrix, Santa Clara, CA) [32]. CEL 
files were normalized using GCRMA [33] for application 
of updated TC algorithm. MAS5 normalization was also 
performed when necessary, e.g. for calculation of GEP70 
and UAMS molecular subtypes. All expression data was 
normalized using R Bioconductor and transformed to the 
UAMS TT2 and TT3 NDMM standard according to a 
variant of M-ComBat [34].
Updated TC classifier
An updated GEP-based TC classifier was developed 
(TC-6) which reflects the primary molecular events in 
MM. The model was trained on the NDMM TT set of 902 
cases using a support vector machine (SVM) [35] where 
translocation groups were identified according to clear 
gene expression spikes with remaining non-translocated 
cases classified according to cyclin-D dysregulation. 
The model uses 24 probes chosen for their power to 
discriminate translocation and cyclin-D dysregulated 
subgroups and is available online at http://github.com/
SteinCK/TC-6 for public use.
We have simplified the original eight to six primary 
subgroups, classifying non-translocated MM into two groups 
according to deregulation of D-group cyclin (D1 or D2) 
without a hybrid class with expression in both, i.e. D1 + D2. 
This reflects our inability to elicit a cluster with expression 
in both CCND1 and CCND2 that is a distinct entity apart 
from the D1 and D2 subgroups. Additional analysis of NGS 
copy number data also supports the existence of a singular 
D1-HRD subgroup, where a homogeneous cohort with copy 
number gains of chromosomes 5, 9, 15, 19, and, uniquely, 
11, emerges that also identifies as D1-HRD according to 
TC-6 classification [36].
The methods used to perform subgroup 
determinations were also updated considerably from 
original TC methodology in that determinations are 
now performed simultaneously with an advanced 
classification system (SVM) rather than in a dichotomous 
step-wise fashion using simple binary thresholds. This 
allows for more sophisticated discrimination for each 
individual case that weighs the entire composition of gene 
expression to form an optimal subgroup determination 
rather than individual probes with binary outcomes. We 
also address sample purity and contamination concerns 
in our methodology by including healthy, normal plasma 
cell (NPC) sample controls as a distinct subgroup in 
model training. Thus across our heterogeneous data set 
we limited our analyses to samples that failed to cluster 
with the NPC contamination cluster. In addition, we built 
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this classifier on GCRMA rather than MAS5 normalized 
expression data as GCRMA normalization has been 
shown to improve overall accuracy in comparative studies 
[37,38]. This updated TC-6 model validated well on an 
external set of 259 GEP samples from the MRC-IX trial 
[39,40], where it accurately predicted iFISH translocation 
designations (Supplementary Table 1).
All statistical analyses were performed in R with 
primary use of the survival [41], party [42], glmnet 
[43], and e1071 [44] packages. Differential expression 
analysis of associations between mutation and GEP data 
was performed with limma [45]. All p-values reported 
for contingency tables, continuous variable, and survival 
comparisons were determined by Fisher’s exact tests, 
Wilcoxon signed rank tests, and log-rank tests, respectively. 
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